Share on StockTwits

Sunesis Pharmaceuticals (NASDAQ:SNSS) was downgraded by research analysts at Wedbush from an “outperform” rating to a “neutral” rating in a report released on Friday, reports.

Shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) opened at 7.78 on Friday. Sunesis Pharmaceuticals has a 52-week low of $3.84 and a 52-week high of $8.46. The stock’s 50-day moving average is $6.69 and its 200-day moving average is $6.05. The company’s market cap is $470.2 million.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.20) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.17) by $0.03. The company had revenue of $2.00 million for the quarter, compared to the consensus estimate of $1.32 million. During the same quarter in the prior year, the company posted $0.18 earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis. Analysts expect that Sunesis Pharmaceuticals will post $-0.74 EPS for the current fiscal year.

Sunesis Pharmaceuticals, Inc (NASDAQ:SNSS) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.